In the Phase 2a part of the study, all 7 participants (4 AChR Ab+, 2 MuSK Ab+, 1 triple [AChR, MuSK, low density lipoprotein receptor‐related protein 4] seronegative) who received six weekly infusions of Descartes‐08 demonstrated clinically meaningful improvements in common MG severity scales at Month 3, as defined by a reduction of at least 2 points on the MG Activities of Daily Living scale (MG‐ADL) and at least 3 points on both the MG Composite (MGC) and Quantitative MG (QMG) scales [10, 11, 12]. This evidence concerns the gene MUSK and myasthenia gravis.